JY
SER icon

Jeff Yass’s Serina Therapeutics SER Stock Holding History

Jeff Yass’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,237
Closed -$81.5K – 14132
2025
Q2 		$81.5K Buy
+13,237
New +$75.2K ﹤0.01% 11900
2024
Q1 		– Sell
-707
Closed -$9.57K – 13553
2023
Q4 		$9.57K Buy
707
+17
+2% +$313 ﹤0.01% 12078
2023
Q3 		$16.5K Sell
690
-551
-44% -$14.6K ﹤0.01% 11646
2023
Q2 		$39K Buy
1,241
+371
+43% +$7.94K ﹤0.01% 11431
2023
Q1 		$20.3K Sell
870
-619
-42% -$14.2K ﹤0.01% 12048
2022
Q4 		$28.9K Buy
+1,489
New +$31.4K ﹤0.01% 11632
2022
Q2 		– Sell
-421
Closed -$13K – 14115
2022
Q1 		$13K Sell
421
-333
-44% -$9.48K ﹤0.01% 12720
2021
Q4 		$29K Buy
+754
New +$20.4K ﹤0.01% 12753
2019
Q4 		– Sell
-302
Closed -$21K – 10807
2019
Q3 		$21K Sell
302
-321
-52% -$30.4K ﹤0.01% 9942
2019
Q2 		$80K Buy
+623
New +$84.3K ﹤0.01% 9701

Other funds holding SER

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
WA
Waverly Advisors Birmingham, Alabama $17.2B AUM 24.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LW
Linscomb Wealth Houston, Texas $2.31B AUM 28.23% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.69B AUM 20.79% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's SER Position: Q3 2025 in Review

Jeff Yass sold out of Serina Therapeutics (SER) in Q3 2025, closing a stake of 13,237 shares — an estimated $81.5K sold.

Jeff Yass first reported a position in SER in Q2 2019 and held it in 10 quarters. The position peaked at $81.5K in Q2 2025. 25 funds tracked by Wall St. Rank hold SER as of Q3 2025.

  • Jeff Yass reported no remaining Serina Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jeff Yass sold 13,237 Serina Therapeutics shares in Q3 2025, an estimated $81.5K.
  • Jeff Yass first reported a position in Serina Therapeutics in Q2 2019 and held it in 10 quarters.
  • Jeff Yass's Serina Therapeutics position peaked at $81.5K in Q2 2025.
  • 25 funds tracked by Wall St. Rank held Serina Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.